OB:AKBM-ME

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Aker BioMarine AS, a biotechnology company, develops krill-derived ingredients and products for nutraceutical, aquaculture, and animal feed applications. More Details


Snowflake Analysis

Reasonable growth potential with imperfect balance sheet.


Similar Companies

Share Price & News

How has Aker BioMarine's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AKBM-ME is not significantly more volatile than the rest of Norwegian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: Insufficient data to determine AKBM-ME's volatility change over the past year.


Market Performance


7 Day Return

23.0%

AKBM-ME

-3.5%

NO Food

2.4%

NO Market


1 Year Return

n/a

AKBM-ME

-9.7%

NO Food

-2.2%

NO Market

Return vs Industry: Insufficient data to determine how AKBM-ME performed against the Norwegian Food industry.

Return vs Market: Insufficient data to determine how AKBM-ME performed against the Norwegian Market.


Shareholder returns

AKBM-MEIndustryMarket
7 Day23.0%-3.5%2.4%
30 Day32.6%4.7%11.5%
90 Day15.3%-1.0%6.9%
1 Yearn/a-8.4%-9.7%1.4%-2.2%
3 Yearn/a44.3%30.6%8.9%-3.3%
5 Yearn/a104.1%63.9%53.3%23.0%

Long-Term Price Volatility Vs. Market

How volatile is Aker BioMarine's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Aker BioMarine undervalued compared to its fair value and its price relative to the market?

2.6x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: AKBM-ME (NOK106.14) is trading above our estimate of fair value (NOK45.42)

Significantly Below Fair Value: AKBM-ME is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: AKBM-ME is unprofitable, so we can't compare its PE Ratio to the NO Food industry average.

PE vs Market: AKBM-ME is unprofitable, so we can't compare its PE Ratio to the Norwegian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AKBM-ME's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AKBM-ME's PB Ratio (2.6x) is in line with the NO Food industry average.


Next Steps

Future Growth

How is Aker BioMarine forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

55.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AKBM-ME is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).

Earnings vs Market: AKBM-ME is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AKBM-ME's is expected to become profitable in the next 3 years.

Revenue vs Market: AKBM-ME's revenue (17.4% per year) is forecast to grow faster than the Norwegian market (6.1% per year).

High Growth Revenue: AKBM-ME's revenue (17.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AKBM-ME's Return on Equity is forecast to be low in 3 years time (17.1%).


Next Steps

Past Performance

How has Aker BioMarine performed over the past 5 years?

-44.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AKBM-ME is currently unprofitable.

Growing Profit Margin: AKBM-ME is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AKBM-ME is unprofitable, and losses have increased over the past 5 years at a rate of 44.6% per year.

Accelerating Growth: Unable to compare AKBM-ME's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AKBM-ME is unprofitable, making it difficult to compare its past year earnings growth to the Food industry (18.4%).


Return on Equity

High ROE: AKBM-ME has a negative Return on Equity (-7.16%), as it is currently unprofitable.


Next Steps

Financial Health

How is Aker BioMarine's financial position?


Financial Position Analysis

Short Term Liabilities: AKBM-ME's short term assets ($194.0M) exceed its short term liabilities ($69.5M).

Long Term Liabilities: AKBM-ME's short term assets ($194.0M) do not cover its long term liabilities ($255.4M).


Debt to Equity History and Analysis

Debt Level: AKBM-ME's debt to equity ratio (59.7%) is considered high.

Reducing Debt: AKBM-ME's debt to equity ratio has reduced from 208.1% to 59.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AKBM-ME has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AKBM-ME has less than a year of cash runway if free cash flow continues to reduce at historical rates of 26% each year


Next Steps

Dividend

What is Aker BioMarine current dividend yield, its reliability and sustainability?

2.06%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AKBM-ME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AKBM-ME's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AKBM-ME's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AKBM-ME's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AKBM-ME's dividend in 3 years as they are not forecast to pay a notable one for the Norwegian market.


Next Steps

  • Explore strong dividend paying companies in the Food, Beverage & Tobacco industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average board tenure


CEO

Matts Johansen (44 yo)

5.33yrs

Tenure

US$254,061

Compensation

Mr. Matts Johansen has been Chief Executive Officer at Aker BioMarine ASA since July 1, 2015. Mr. Johansen has been Chief Operating Officer of Aker Biomarine Antarctic AS since June 1, 2012. He serves as P...


CEO Compensation Analysis

Compensation vs Market: Matts's total compensation ($USD0.00) is below average for companies of similar size in the Norwegian market ($USD571.30K).

Compensation vs Earnings: Matts's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Kjell Rokke
Director4.75yrsno datano data
Frank Reite
Director4.75yrsno datano data
Oyvind Eriksen
Director4.75yrsno datano data
Ola Snøve
Chairman6.83yrsUS$56.79k0.21%
$ 19.2m
Sindre Skjong
Employee Representative Director1.25yrsno datano data
Line Johnsen
Employee Representative Director0.42yrno datano data

4.8yrs

Average Tenure

50yo

Average Age

Experienced Board: AKBM-ME's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AKBM-ME insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: AKBM-ME only recently listed within the past 12 months.


Top Shareholders

Company Information

Aker BioMarine AS's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aker BioMarine AS
  • Ticker: AKBM-ME
  • Exchange: OB
  • Founded:
  • Industry: Packaged Foods and Meats
  • Sector: Food, Beverage & Tobacco
  • Market Cap: kr9.109b
  • Shares outstanding: 87.59m
  • Website: https://www.akerbiomarine.com

Number of Employees


Location

  • Aker BioMarine AS
  • OksenOeyveien 10
  • PO Box 496
  • Lysaker
  • Akershus
  • 1327
  • Norway

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AKBM-MEOB (Oslo Bors)YesOrdinary SharesNONOKJul 2020

Biography

Aker BioMarine AS, a biotechnology company, develops krill-derived ingredients and products for nutraceutical, aquaculture, and animal feed applications. The company provides krill oil products, including ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 17:22
End of Day Share Price2020/11/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.